Canada - anglais - Health Canada

modern veterinary therapeutics llc - moxidectin; imidacloprid - solution - 25mg; 100mg - moxidectin 25mg; imidacloprid 100mg - dogs

Canada - anglais - Health Canada

modern veterinary therapeutics llc - moxidectin; imidacloprid - solution - 62.5mg; 250mg - moxidectin 62.5mg; imidacloprid 250mg - dogs

Canada - anglais - Health Canada

modern veterinary therapeutics llc - moxidectin; imidacloprid - solution - 100mg; 400mg - moxidectin 100mg; imidacloprid 400mg - dogs

États-Unis - anglais - NLM (National Library of Medicine)

forreal pharmaceuticals llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocaine ointment usp, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. it is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of lidocaine ointment usp, 5%.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - belimumab -

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

my pet products australia pty. ltd. - ivermectin - oral bolus, chewable - ivermectin anthelmintic active 136.0 ug/chew - parasiticides - dog - 12-22 kg - heartworm - larvae | heartworm - prevention of | to prevent heartworm

Israël - anglais - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - powder for concentrate for solution for infusion - belimumab 120 mg - belimumab - belimumab - benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g., positive anti-dsdna and low complement) despite standard therapy.benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Israël - anglais - Ministry of Health

glaxo smith kline (israel) ltd - belimumab - powder for concentrate for solution for infusion - belimumab 400 mg - belimumab - belimumab - benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g., positive anti-dsdna and low complement) despite standard therapy.benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Union européenne - anglais - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, systemic - immunosuppressants - benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g., positive anti dsdna and low complement) despite standard therapy.benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - belimumab 120mg - powder for injection - 120 mg - active: belimumab 120mg excipient: citric acid monohydrate polysorbate 80 sodium citrate dihydrate sucrose - benlysta is indicated as add-on therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g. ana titre > 1:80 and/or anti-dsdna titre > 30 iu/ml) despite standard therapy. the safety & efficacy of benlysta have not been evaluated in patients with severe active lupus nephritis or severe active cns lupus.